Being in remission from inflammatory bowel disease usually means the symptoms have gone quiet and the last lab report came back reassuring. It rarely means the gut has healed. Research published on 19 September 2026 in the journal Science puts a name on that gap: an Australian team found a persistent, low-grade molecular fault inside the intestinal cells of people whose disease looked well controlled, and the patients carrying the strongest version of it were the ones who relapsed over the following two years. The finding does not add a new test to your next lab slip. It does explain something many readers already live with, which is why a flare can arrive weeks after a normal result.
What remission actually means on a lab report
Doctors use the word remission at three different depths, and lab results sit at different places in that ladder.
Clinical remission means the symptoms have settled: no urgency, no blood, no night-time trips. Endoscopic remission means a camera finds the bowel lining visibly healed. Histological remission means a pathologist finds no inflammation in tissue samples under a microscope. The three do not move together. A person can reach the first without the second, and the second without the third.
That matters because blood and stool markers mostly track the first two. Mayo Clinic describes inflammatory bowel disease as a condition that alternates between flares and quiet periods, and the quiet period is where routine monitoring has the least to work with. Our team covers the ulcerative colitis blood test, and a separate page explains Crohn’s disease symptoms and treatment.
Latest scientific advances: the smoldering defect in gut tissue
The Science paper came from WEHI and the Royal Melbourne Hospital. The team collected roughly 900 biopsies from 80 people, with and without inflammatory bowel disease, and grew miniature intestines, called organoids, from those samples so they could study human tissue rather than mouse models.
What they found is best described as a stuck switch. Intestinal cells in people with the disease were primed to die, through a chain the researchers call a necroptotic-to-apoptotic signalling axis. Necroptosis is a messy, inflammatory form of cell death; apoptosis is the tidy, silent kind. The cells were sitting halfway along that chain, ready to tip. Crucially, the defect was still detectable in patients whose disease appeared well controlled, and in people with only mild disease activity.
The researchers then followed those patients for more than two years. People whose cells showed stronger death signalling were more likely to relapse.
What this means for you: nothing changes at your next appointment. The measurement required detailed laboratory analysis of biopsy tissue, not a tube of blood, and the study’s own authors say a diagnostic test is not close. The value sits in the explanation. It supports the idea that cell death helps drive the disease rather than simply resulting from it, and it gives a biological reason why symptom-free does not mean risk-free.
Why calprotectin and CRP can look fine when the gut is not
The two markers most people are monitored with in remission are fecal calprotectin, measured in stool, and C-reactive protein, measured in blood. Both are useful. Neither was designed to detect what the Melbourne team was looking at.
A prospective study of 253 patients with ulcerative colitis published in Inflammatory Bowel Diseases in 2025 put numbers on the gap. Among patients who were in clinical remission, a fecal calprotectin at or above 50 micrograms per gram was the threshold most useful for flagging those who still had active inflammation in their tissue samples. That is far below the cut-offs many people are told to worry about, and even at that level the test caught only about half of them.
| Marcador | Muestra | What it picks up in remission | What it can miss |
|---|---|---|---|
| Calprotectina fecal | Heces | Inflammation coming from the bowel lining itself | Microscopic tissue inflammation below the usual thresholds |
| proteína C reactiva | Sangre | Inflammation active enough to reach the bloodstream | Limited or rectal disease, which often leaves it normal |
| Biometría hemática (BH) | Sangre | Anemia from bleeding, platelet rise during a flare | Quiet disease with no blood loss |
| Albúmina | Sangre | Protein loss through a badly inflamed bowel wall | Anything short of severe disease |
There is a second, less discussed problem, and it runs the other way. A Japanese study of 61 patients published in BMC Gastroenterology in 2024 looked at people whose colon carried scarring or pseudopolyps from past extensive ulceration. Their calprotectin values ran higher than other patients even in remission, and in that group the test did not predict relapse at all. In other words, a raised number can reflect old damage rather than new inflammation. Our guide explains the fecal calprotectin test, and another page covers high CRP levels.
What research says about predicting the next flare
Better prediction is an active field, and the most useful results so far come from the moment when it matters most, which is stopping treatment.
A study published in Gut in 2024 examined more than 200 immune-related proteins in the blood of people with Crohn’s disease who were coming off infliximab, then validated the findings in a second trial population. Combinations of these proteins separated those who relapsed early from those who stayed well longer, and they outperformed both C-reactive protein and fecal calprotectin at the task. This is research-grade work, not a panel you can request, but it shows the direction of travel.
A randomised trial reported in Gut in 2025 makes the same point from a different angle. Among 140 patients in confirmed remission, withdrawing anti-tumour necrosis factor treatment did not change how many stayed in clinical remission at one year. It did change the markers: significantly more people in the withdrawal group had a fecal calprotectin above 250 micrograms per gram by the end. The objective signal moved before the symptoms did.
What to do with your own results while you are well
Three habits get the most out of ordinary monitoring.
- Read the trend, not the snapshot. A calprotectin of 90 means one thing after a run of results near 30 and another after a run near 200. A single value carries much less information than the direction it is moving.
- Read stool and blood together. A normal C-reactive protein alongside a rising calprotectin is a common and meaningful pattern, and it is the combination that a gastroenterologist reads, not either line alone.
- Keep the appointments you feel well enough to skip. Periodic calprotectin testing and scheduled endoscopy exist precisely to catch inflammation that has not yet announced itself. Our guide also explains blood tests for inflammation.
Cuándo consultar a tu médico
Contact your team without waiting for a scheduled test if blood returns to your stool, if diarrhea lasts more than two weeks, if urgency starts waking you at night, or if you lose weight without trying. Seek urgent care for a combination of frequent bloody stools, fever and rapid weight loss. The Centers for Disease Control and Prevention estimates that 2.4 to 3.1 million adults in the United States live with inflammatory bowel disease, so these symptoms are common enough to be taken seriously rather than waited out. Another article explains irritable bowel syndrome, which shares several symptoms and is often the reason a calprotectin test is ordered in the first place.
Glosario
| Término | Definición |
|---|---|
| Remisión | A period when the disease is quiet. It describes activity, not cure, and comes in clinical, endoscopic and histological forms. |
| Brote | A return or worsening of symptoms after a quiet period. |
| Calprotectina fecal | Una proteína liberada por los glóbulos blancos en el intestino. Se mide en las heces e indica inflamación del revestimiento intestinal. |
| Histological remission | No inflammation visible in tissue samples under a microscope. The deepest of the three levels. |
| Organoid | A miniature tissue grown in the laboratory from a patient’s own cells, used to study a disease in human material. |
| Necroptosis | A form of cell death that spills contents and triggers inflammation, unlike the silent, tidy kind. |
| Pseudopolyp | A raised area of scar tissue left behind by past ulceration. It is not a tumour, but it can distort test results. |
Preguntas frecuentes
If I am in remission and my calprotectin is normal, am I safe from a flare?
No, and that is the practical message of the new work. A normal result lowers the probability of active inflammation but does not remove it. Tissue-level inflammation can persist below the thresholds a stool test reports, which is why gastroenterologists still schedule periodic endoscopy in people who feel entirely well.
Why is my calprotectin high when I have no symptoms at all?
Several reasons compete. Inflammation can be active without being felt. Common painkillers of the anti-inflammatory family raise the value. An intestinal infection raises it. And if your colon carries scarring from past severe disease, the number can sit higher permanently. Your doctor reads it against your own previous results rather than against a universal line.
Does this study mean a new test for predicting flares is coming?
Not soon. The measurement required biopsy tissue and detailed molecular analysis in a research laboratory. The authors describe it as a foundation for developing better prognostic tools, not as a tool itself. Nothing comparable is available to order today.
Should I ask to stop my treatment if I have been in remission for years?
That is a conversation for your gastroenterologist, and the trial evidence is genuinely mixed. Withdrawal did not worsen one-year clinical remission rates in a randomised study, but objective markers of inflammation rose in the group that stopped. Decisions of this kind depend on how deep your remission is, how long it has lasted and what your endoscopy showed.
Which is more useful in remission, a stool test or a blood test?
For detecting inflammation inside the intestine, the stool marker is generally the more informative of the two, because it is produced at the site of the problem. Blood work does a different job: tracking anemia, nutrition and the wider impact of the disease. They answer separate questions rather than competing.
Fuentes
The scientific references below were identified through PubMed and are linked to their original publications.
- Centers for Disease Control and Prevention – IBD Facts and Stats: prevalence and burden of inflammatory bowel disease in the United States – cdc.gov
- National Institute of Diabetes and Digestive and Kidney Diseases – Crohn’s disease: symptoms, diagnosis, treatment and maintaining remission – National Institutes of Health – niddk.nih.gov
- Mayo Clinic – Inflammatory bowel disease: symptoms and causes – mayoclinic.org
- Pang J., Al-Ani A. H., Samson A. L., Vince J. E., Murphy J. M. et al. – A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease – Science, 2026 – doi.org/10.1126/science.aeh7112
- Hahn G. D., Lakatos P. L., Bessissow T. et al. – Defining fecal calprotectin cutoffs that predict endoscopic and histologic remission in patients with ulcerative colitis – Inflammatory Bowel Diseases, 2025 – doi.org/10.1093/ibd/izaf008
- Ishida N., Osawa S., Sugimoto K. et al. – Effect of past extensive ulcers on fecal calprotectin in ulcerative colitis – BMC Gastroenterology, 2024 – doi.org/10.1186/s12876-024-03522-2
- Pierre N., Meuwis M.-A., Louis E. et al. – External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn’s disease stopping infliximab – Gut, 2024 – doi.org/10.1136/gutjnl-2024-332648
- Gisbert J. P., Chaparro M., Panés J. et al. – Withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU – Gut, 2025 – doi.org/10.1136/gutjnl-2024-333385
- Costa M. H. M., Sassaki L. Y., Chebli J. M. F. – Fecal calprotectin and endoscopic scores: the cornerstones in clinical practice for evaluating mucosal healing in inflammatory bowel disease – World Journal of Gastroenterology, 2024 – doi.org/10.3748/wjg.v30.i24.3022
Lecturas recomendadas
- Análisis de sangre para colitis ulcerosa: qué muestran realmente tus resultados
- Resultados de la prueba de calprotectina fecal: qué indican tus niveles
- Crohn’s disease: symptoms, diagnosis and treatment
- High CRP levels: what your result really means
- Irritable bowel syndrome: symptoms, tests and treatment
Entiende tus resultados de laboratorio con AI DiagMe
A monitoring report in remission mixes a stool marker with a blood count, an inflammation protein and a nutritional value, and the useful information sits in how those lines move together over months rather than in any single number. AI DiagMe reads your blood, urine and stool results and turns them into plain language, so you walk into your next appointment knowing which values shifted and which questions are worth asking. It helps you understand your results; it does not make a diagnosis and does not replace your doctor.
Obtén la lectura de tus resultados en minutos
